Amyris Biotechnologies (AMRS) and Its Peers Head to Head Survey

Amyris Biotechnologies (NASDAQ: AMRS) is one of 25 public companies in the “Industrial organic chemicals” industry, but how does it compare to its peers? We will compare Amyris Biotechnologies to related companies based on the strength of its analyst recommendations, profitability, institutional ownership, dividends, earnings, risk and valuation.

Analyst Ratings

This is a summary of recent recommendations and price targets for Amyris Biotechnologies and its peers, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Amyris Biotechnologies 0 1 2 0 2.67
Amyris Biotechnologies Competitors 120 479 744 26 2.49

Amyris Biotechnologies currently has a consensus target price of $9.67, indicating a potential upside of 52.47%. As a group, “Industrial organic chemicals” companies have a potential upside of 10.33%. Given Amyris Biotechnologies’ stronger consensus rating and higher probable upside, analysts plainly believe Amyris Biotechnologies is more favorable than its peers.


This table compares Amyris Biotechnologies and its peers’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Amyris Biotechnologies -53.95% N/A -89.90%
Amyris Biotechnologies Competitors -17.73% -14.01% -6.55%

Institutional and Insider Ownership

19.3% of Amyris Biotechnologies shares are owned by institutional investors. Comparatively, 52.6% of shares of all “Industrial organic chemicals” companies are owned by institutional investors. 11.3% of Amyris Biotechnologies shares are owned by company insiders. Comparatively, 14.0% of shares of all “Industrial organic chemicals” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Volatility and Risk

Amyris Biotechnologies has a beta of 0.12, suggesting that its stock price is 88% less volatile than the S&P 500. Comparatively, Amyris Biotechnologies’ peers have a beta of 0.49, suggesting that their average stock price is 51% less volatile than the S&P 500.

Earnings & Valuation

This table compares Amyris Biotechnologies and its peers gross revenue, earnings per share and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Amyris Biotechnologies $143.45 million -$72.32 million -2.08
Amyris Biotechnologies Competitors $3.36 billion $346.16 million 4.24

Amyris Biotechnologies’ peers have higher revenue and earnings than Amyris Biotechnologies. Amyris Biotechnologies is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.


Amyris Biotechnologies peers beat Amyris Biotechnologies on 8 of the 12 factors compared.

About Amyris Biotechnologies

Amyris, Inc. provides various alternatives to a range of petroleum-sourced products worldwide. The company uses its industrial bioscience technology to design microbes primarily yeast, as well as to convert plant-sourced sugars into renewable ingredients. It produces and sells Biofene that converts to squalane, which is used as an emollient in cosmetics and other personal care products; and natural oils and aroma chemicals for the flavors and fragrances market. The company also provides renewable solvents, polymers, and lubricants for industrial markets; Biofene ingredients for nutraceuticals and vitamins market; and renewable fuels for transportation fuels markets. It has a collaboration partnership with Total S.A. to produce and commercialize Biofene-based diesel and jet fuels. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was founded in 2003 and is headquartered in Emeryville, California.

Receive News & Ratings for Amyris Biotechnologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amyris Biotechnologies and related companies with's FREE daily email newsletter.

Leave a Reply